Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Ophthalmology
|
| gptkbp:administered_by |
gptkb:cream
|
| gptkbp:approves |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:brand |
gptkb:Alphagan
Alphagan P 0.1% Alphagan P 0.15% |
| gptkbp:class |
alpha-2 adrenergic agonist
|
| gptkbp:clinical_trial |
NCT00000123
NCT00000124 NCT00000125 |
| gptkbp:clinical_use |
adjunctive therapy
long-term management of glaucoma |
| gptkbp:contraindication |
hypersensitivity to brimonidine
use in infants |
| gptkbp:dosage_form |
gptkb:Software_Solutions
|
| gptkbp:effective_date |
2001-04-30
|
| gptkbp:financial_support |
do not drive after use
wait 15 minutes before wearing contact lenses |
| gptkbp:form |
prescription only
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alphagan P
|
| gptkbp:indication |
gptkb:ocular_hypertension
gptkb:open-angle_glaucoma |
| gptkbp:ingredients |
brimonidine tartrate
|
| gptkbp:interacts_with |
antidepressants
MAO inhibitors sedatives |
| gptkbp:manufacturer |
gptkb:Allergan
|
| gptkbp:mechanism_of_action |
reduces aqueous humor production
increases uveoscleral outflow |
| gptkbp:packaging |
gptkb:bottle
|
| gptkbp:research |
Cost-effectiveness analysis
Long-term safety studies Impact on quality of life Efficacy in pediatric patients Comparative studies with other glaucoma medications |
| gptkbp:route_of_administration |
topical
|
| gptkbp:safety_features |
generally well tolerated
monitor for allergic reactions monitor for systemic effects |
| gptkbp:side_effect |
fatigue
headache drowsiness dry mouth burning sensation in the eye |
| gptkbp:storage |
store at room temperature
|
| gptkbp:strength |
0.1% and 0.15%
|
| gptkbp:used_for |
gptkb:Ophthalmology
|
| gptkbp:bfsParent |
gptkb:Alphagan
|
| gptkbp:bfsLayer |
7
|